These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 1204244)

  • 1. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properdin deficiency in a family with fulminant meningococcal infections.
    Sjöholm AG; Braconier JH; Söderström C
    Clin Exp Immunol; 1982 Nov; 50(2):291-7. PubMed ID: 7151327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.
    Lachmann PJ; Halbwachs L
    Clin Exp Immunol; 1975 Jul; 21(1):109-14. PubMed ID: 52423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation of an early component of complement and Hageman factor in C3 destruction by zymosan.
    Gigli I; Koethe S; Austen KF
    Clin Immunol Immunopathol; 1975 Jul; 4(2):189-98. PubMed ID: 1170051
    [No Abstract]   [Full Text] [Related]  

  • 8. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
    Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
    Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that C1s participates in the alternative complement pathway.
    Volanakis JE; Schultz DR; Stroud RM
    Int Arch Allergy Appl Immunol; 1976; 50(1):68-80. PubMed ID: 1244208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
    Ruley EJ; Forristal J; Davis NC; Andres C; West CD
    J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
    Yukiyama Y; Lew FT; Waks HS; Osler AG
    J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins.
    Nydegger UE; Fearon DT; Austen KF
    J Immunol; 1978 Apr; 120(4):1404-8. PubMed ID: 565382
    [No Abstract]   [Full Text] [Related]  

  • 14. Dissociation of anticomplementary and adjuvant properties of proteins derived from cobra venom.
    Morrison DC; Louis JA; Weigle WO
    Immunology; 1976 Mar; 30(3):317-23. PubMed ID: 56310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of the classical and alternative complement pathways in chemotaxis of human C2 deficiency (author's transl)].
    Pham Huu T; Buriot D; Griscelli C
    Ann Immunol (Paris); 1980; 131C(1):69-77. PubMed ID: 7396417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
    Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
    J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and quantitation in plasma and synovial fluid of a fragment of human C4 with alpha mobility generated during the activation of the complement system.
    Perrin LH; Shiraishi S; Stroud RM; Lambert PH
    J Immunol; 1975 Jul; 115(1):32-5. PubMed ID: 1171140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative pathway of complement in sickle cell disease.
    Strauss RG; Asbrock T; Forristal J; West CD
    Pediatr Res; 1977 Apr; 11(4):285-9. PubMed ID: 846782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.